{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:08:04Z","timestamp":1788984484652,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.urolonc.2020.07.003","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T13:04:11Z","timestamp":1596287051000},"page":"76.e9-76.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia"],"prefix":"10.1016","volume":"39","author":[{"given":"Daniel A.","family":"Gonz\u00e1lez-Padilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Gonz\u00e1lez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rodr\u00edguez-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Garc\u00eda-Jarabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Corona-laPuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Rodr\u00edguez-Antol\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Villacampa-Aub\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.07.003_bib0001","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0002","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.euf.2018.06.018","article-title":"Manufacturing and the market: rationalizing the shortage of Bacillus Calmette-Gu\u00e9rin","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0003","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0004","first-page":"9480","article-title":"Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer","volume":"25","author":"Siracusano","year":"2018","journal-title":"Can J Urol"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0005","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","article-title":"The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Gu\u00e9rin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial","volume":"190","author":"Gontero","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3233\/BLC-170138","article-title":"Defining priorities to improve patient experience in non-muscle invasive bladder cCancer","volume":"4","author":"Garg","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0007","unstructured":"FACIT Measurement System. FACT-Bl (Version 4). n.d. Available at: https:\/\/www.facit.org\/FACITOrg\/Questionnaires. Accessed December 9, 2019."},{"key":"10.1016\/j.urolonc.2020.07.003_bib0008","unstructured":"International Consultation on Benign Prostatic Hyperplasia (2nd\u202f: 1993: Paris F, Cockett ATK, Khoury S, Aso Y, Chatelain C, Griffiths K, et al. The 2nd [Second] International Consultation on Benign Prostatic Hyperplasia (BPH, Paris, June 27-30, 1993\u202f: proceedings. Jersey\u202f: Scientific Communication International; 1993."},{"key":"10.1016\/j.urolonc.2020.07.003_bib0009","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) n.d. Available at:https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed December 9, 2019."},{"key":"10.1016\/j.urolonc.2020.07.003_bib0010","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0011","series-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5152\/tud.2018.30040","article-title":"Assessment of the quality of life and sexual functions of patients followed-up for non-muscle invasive bladder cancer: preliminary results of the prospective-descriptive study","volume":"44","author":"Bolat","year":"2018","journal-title":"Turk J Urol"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0013","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1179\/1973947813Y.0000000126","article-title":"The quality of life in patients during intravesical treatment and correlation with local symptoms","volume":"26","author":"Wei","year":"2014","journal-title":"J Chemother Florence Italy"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0014","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/BLC-150029","article-title":"Treatment decision making in patients with bladder cancer","volume":"1","author":"Berry","year":"2015","journal-title":"Bladder Cancer Amst Neth"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0015","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus Calmette-Gu\u00e9rin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0016","doi-asserted-by":"crossref","first-page":"82567","DOI":"10.18632\/oncotarget.12856","article-title":"Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis","volume":"7","author":"Zhuo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0017","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","article-title":"Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer","volume":"32","author":"Sousa","year":"2016","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0018","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.003_bib0019","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.acuro.2018.07.006","article-title":"Life quality evaluation in patients with bladder cancer: a systematic review","volume":"43","author":"Mina","year":"2019","journal-title":"Actas Urol Esp"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:18:49Z","timestamp":1761041929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1078143920303252"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}